Quotient Bioresearch acquires Edinburgh clinical research facility

Cambridgeshire, UK, 18th May 2009 – Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new strategic business unit within Quotient - Quotient Clinical.

Download press release PDF